Merck Sharp + Dohme Corp.

Brandon A Vara

Zachary G Brill

Jared N Cumming

Amjad Ali

Kun Liu

Joey Lee Methot

Phieng Siliphaivanh

Thomas H Graham

Jing Su

Rongze Kuang

Umar Faruk Mansoor

Abdelghani Achab

Xavier Fradera

Qiaolin Deng

Yeon-Hee Lim

Yonglian Zhang

Erin F DiMauro

Matthew A Larsen

Huijun Wang

Gioconda V Gallo-Etienne

Duane Demong

Jesus Moreno

In its many embodiments, the present invention provides certain substituted amino triazolopyrimidine and amino triazolopyrazine compounds of Formula (IA) and Formula (IB): and, and pharmaceutically acceptable salts thereof, wherein, R, n, R, and Rare as defined herein, pharmaceutical compositions comprising one or more such compounds (alone and in combination with one or more other therapeutically active agents), and methods for their preparation and use, alone and in combination with other therapeutic agents, as antagonists of A2a and/or A2b receptors, and their use in the treatment of a variety of diseases, conditions, or disorders that are mediated, at least in part, by the adenosine A2a receptor and/or the adenosine A2b receptor.

Substituted amino triazolopyrimidine and amino triazolopyrazine adenosine receptor antagonists, pharmaceutical compositions and their use

Described herein are compounds of Formula I: or a pharmaceutically acceptable salt thereof, wherein A, R, R, R, W, X, Y, Z, m, n and p are as defined herein. The compounds of Formula I act as RIPK1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for RIPK1-related diseases.

Spirotricycle RIPK1 inhibitors and methods of uses thereof

Growing community of inventors

Boston, MA, United States of America

Brandon A Vara